Lectin-Based Isolation of Colorectal Cancer Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively isolate and characterize colorectal cancer stem cells due to the lack of specific markers, making it difficult to detect and study these cells, which are crucial for understanding tumor progression and resistance to treatments.
Innovation Solution
The use of lectins that recognize specific sugar units, such as Ulex europaeus Agglutinin 1 (UEA-1) or Trichosanthes japonica Agglutinin II, to label and isolate colorectal cancer stem cells, combined with other lectins that recognize the T antigen, for enhanced detection and isolation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to isolate cancer stem cells, then the process is simple, but the detection and isolation efficiency is poor due to lack of specific markers
Solution Approach 1:
The patent uses lectins as intermediary substances that bind to specific sugar markers (fucose α1-2 galactose unit and T antigen) on the surface of cancer stem cells. These lectins serve as mediators between the detection system and the cancer stem cells, enabling specific recognition and isolation without requiring direct interaction with the cells themselves. This resolves the contradiction by providing specific detection capability through the intermediary lectin molecules.
Solution Approach 2:
The patent changes the detection parameter from generic cell markers to specific carbohydrate markers (fucose α1-2 galactose unit and T antigen) that are uniquely expressed on cancer stem cells. By shifting the detection focus to these specific molecular parameters, the method achieves high detection efficiency while maintaining reasonable complexity through targeted molecular recognition rather than complex multi-parameter analysis.
2Measurement precision
If specific markers are searched for cancer stem cells, then detection accuracy improves, but the time required for characterization increases
Solution Approach 1:
The patent performs preliminary identification of cancer stem cells using lectins that recognize specific sugar markers before proceeding to further characterization. This preliminary action using UEA-1 and TJA-II lectins allows for rapid initial sorting and enrichment of cancer stem cells, reducing the time needed for subsequent characterization steps by starting with a pre-enriched population rather than analyzing all cells from scratch.
3Productivity
If multiple lectins are used for labeling, then isolation efficiency improves, but the complexity of the labeling system increases
Solution Approach 1:
The patent combines multiple lectins (UEA-1 recognizing fucose α1-2 galactose unit and TJA-II recognizing T antigen) into a unified labeling system that works synergistically. Rather than treating them as separate complex systems, the invention merges their specificities into a coordinated approach where both lectins can be used together to enhance isolation efficiency, managing the complexity through integrated application rather than separate procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the effective enrichment of colorectal cancer stem cells, improving their detection and isolation efficiency compared to existing methods, enabling better understanding and potential targeting of these cells for treatment.
Implementation Method 1
the fucose α 1-2 galactose unit expressed on the surface of colorectal cancer stem cells enables detection and optionally isolation of these cells using a lectin that recognizes this unit
Implementation Method 2
at least one second lectin that recognizes the T antenna, in particular two lectins that recognize the T antenna
Data Source
AI summary
The invention relates to the use of a lectin that recognizes the fucose α 1-2 galactose unit, as a first means for labeling and optionally a second means for labelling colorectal cancer stem cells, in particular a lectin that recognizes the T antigen, in order to carry out a method for the detection and optionally isolation of colorectal cancer stem cells, a method for the detection and optionally isolation of colorectal cancer stem cells for research purposes, and a method for the in vitro diagnosis of colorectal cancer recurrence risk and/or aggressiveness so as to define a prognostic value in order to make colorectal cancer therapy adjustments, as well as a kit comprising a lectin that recognizes the fucose α 1-2 galactose unit and a lectin that recognizes the T antigen.